Russell Investments Group Ltd. Has $10.98 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Russell Investments Group Ltd. increased its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 15.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 125,902 shares of the biotechnology company's stock after buying an additional 16,874 shares during the period. Russell Investments Group Ltd. owned 0.20% of Blueprint Medicines worth $10,981,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Envestnet Asset Management Inc. grew its stake in shares of Blueprint Medicines by 13.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 32,115 shares of the biotechnology company's stock worth $2,801,000 after acquiring an additional 3,723 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Blueprint Medicines in the 4th quarter worth $212,000. Pitcairn Co. raised its position in shares of Blueprint Medicines by 2.8% during the fourth quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company's stock valued at $925,000 after buying an additional 293 shares during the last quarter. Cinctive Capital Management LP raised its position in shares of Blueprint Medicines by 29.2% during the fourth quarter. Cinctive Capital Management LP now owns 96,048 shares of the biotechnology company's stock valued at $8,377,000 after buying an additional 21,707 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Blueprint Medicines by 7.0% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 269,990 shares of the biotechnology company's stock valued at $23,549,000 after buying an additional 17,754 shares during the period.

Remove Ads

Blueprint Medicines Trading Up 0.4 %

Shares of BPMC traded up $0.36 on Wednesday, reaching $81.81. 519,538 shares of the company's stock were exchanged, compared to its average volume of 767,621. The business has a 50 day moving average price of $89.79 and a two-hundred day moving average price of $93.39. Blueprint Medicines Co. has a 12 month low of $73.04 and a 12 month high of $121.90. The stock has a market capitalization of $5.23 billion, a P/E ratio of -75.75 and a beta of 0.75. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Research analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the completion of the transaction, the insider now directly owns 18,270 shares in the company, valued at $1,692,167.40. This trade represents a 14.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Christina Rossi sold 2,274 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the sale, the chief operating officer now owns 69,266 shares in the company, valued at approximately $6,581,655.32. This represents a 3.18 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,358 shares of company stock worth $2,583,187. Corporate insiders own 4.21% of the company's stock.

Wall Street Analysts Forecast Growth

BPMC has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. JMP Securities restated a "market outperform" rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Jefferies Financial Group assumed coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They issued a "buy" rating and a $135.00 target price on the stock. Stephens restated an "overweight" rating and set a $140.00 price target on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Finally, Wolfe Research started coverage on Blueprint Medicines in a research note on Tuesday, March 18th. They issued an "outperform" rating on the stock. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $124.95.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.